Uso de Aducanumab como tratamiento del Alzheimer

Alzheimer's is a disease that causes a progressive cognitive deterioration of the elderly whose social implications are severe due to the loss in their ability to carry out their daily activities, which makes them highly dependent. Unfortunately, there is no cure for this disease and until a few decades ago, only non-pharmacological alternatives had been used to treat these patients and the use of drugs to control symptoms. However, with the advancement of science in recent years, drugs have been developed that delay the progression of the disease, among which acetylcholinesterase inhibitors stand out, and N-methyl-daspartic acid receptor (NMDAR) antagonists, without However, the results have not been as expected. In recent years, drugs based on monoclonal antibodies have emerged, among which aducanumab stands out, which offers hope for the treatment of the disease. Given the expectation of the same, a review of 300 articles was made in the Scopus, Medline, and Pubmed databases. Scielo and Latindex, of which 36 were selected based on the inclusion criteria to address pharmacological treatments for Alzheimer's, the experience in the use of aducanumab, highlighting the benefits, side effects and obstacles to the adoption of its use by from the patients. The results reveal that this type of drug offers hope by finding a decrease in the cognitive deterioration of the treated patients, but there are controversies regarding its use in the first place due to the cost-benefit ratio, which means that the treatment is not viable to be assumed by the public health systems, in addition to various side effects such as cerebral edema (35%), cerebral hemorrhage (21%), likewise headache and confusion have been reported in 47 and 15 % of patients respectively, so the drug is not totally safe. El Alzheimer es una enfermedad que causa un deterioro cognitivo progresivo de las personas de la tercera edad cuyas implicaciones sociales son severas debido a la perdida en su capacidad para llevar a sus actividades diarias lo cual la hace altamente dependiente. Desafortunadamente esta enfermedad no tiene curación y hasta hace pocas décadas solamente se había recurrido a alternativas no farmacológicas para el abordaje de estos pacientes y el uso de fármacos para el control de los síntomas. No obstante con el avance de la ciencia en los últimos años se han desarrollado fármacos que retrasan la progresión de la enfermedad entre los que destacan los inhibidores de la acetilcolinesterasa